Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare

Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW (2006) Serum urate levels and gout flares analysis from managed care data. J Clin Rheumatol 12:61–65. https://doi.org/10.1097/01.rhu.0000209882.50228.9f

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42. https://doi.org/10.1136/annrheumdis-2016-209707

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald T, Nuki G, Pywell A, Zhang W, Roddy E, British Society for Rheumatology Standards, Audit and Guidelines Working Group (2017) The British Society For Rheumatology guideline for the management of gout. Rheumatology 56:e1–e20. https://doi.org/10.1093/rheumatology/kex150

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446. https://doi.org/10.1002/acr.21772

Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765–1770. https://doi.org/10.1136/annrheumdis-2012-201687

Becker MA, MacDonald PA, Hunt BJ et al (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27:585–591. https://doi.org/10.1080/15257770802136032

Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 10:1–11. https://doi.org/10.1186/1477-7525-10-117

Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA (2011) Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 14:10–15. https://doi.org/10.3111/13696998.2010.540874

Wortmann RL, MacDonald PA, Hunt B, Jackson RL (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32:2386–2397. https://doi.org/10.1016/j.clinthera.2011.01.008

Dalbeth N, Choi HK, Terkeltaub R (2017) Gout: a roadmap to approaches for improving global outcomes. Arthritis Rheumatol 69:22–34. https://doi.org/10.1002/art.39799

Rashid N, Levy GD, Wu Y-L, Zheng C, Koblick R, Cheetham TC (2015) Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int 35:1799–1807. https://doi.org/10.1007/s00296-015-3284-3

Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR (2009) The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 15:3–7. https://doi.org/10.1097/RHU.0b013e3181945d2c

Wu E, Patel P, Mody R et al (2009) Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 36:1032–1040. https://doi.org/10.3899/jrheum.080487

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ (2019) Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology. https://doi.org/10.1093/rheumatology/key402

Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https://doi.org/10.1136/bmj.b2393

Wood AM, White IR, Royston P (2008) How should variable selection be performed with multiply imputed data? Stat Med 27:3227–3246. https://doi.org/10.1002/sim.3177

Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 67:960–966. https://doi.org/10.1136/ard.2007.076232

Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, Evans RR (2014) Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 41:1703–1711. https://doi.org/10.3899/jrheum.131226

Schlesinger N, Mysler E, Lin H-Y, de Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264–1271. https://doi.org/10.1136/ard.2010.144063

Mitha E, Ralph Schumacher H, Fouche L et al (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatol (United Kingdom) 52:1285–1292. https://doi.org/10.1093/rheumatology/ket114

Schumacher HR, Evans RR, Saag KG et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 64:1462–1470. https://doi.org/10.1002/acr.21690

Schumacher HR, Sundy JS, Terkeltaub R et al (2012) Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64:876–884. https://doi.org/10.1002/art.33412

Kang D, Park S, Lee I, Johnson R (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16:3553–3562. https://doi.org/10.1681/asn.2005050572

Grainger R, McLaughlin RJ, Harrison AA, Harper JL (2012) Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatol (United Kingdom) 52:1018–1021. https://doi.org/10.1093/rheumatology/kes326

Keenan T, Blaha M, Nasir K et al (2012) Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol 110:1787–1792. https://doi.org/10.1016/j.amjcard.2012.08.012

Mason JC, Libby P (2015) Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 36:482–489. https://doi.org/10.1093/eurheartj/ehu403

Kaplan RC, Frishman WH (2001) Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 3:326–332. https://doi.org/10.1097/00132580-200109000-00009

Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321–325. https://doi.org/10.1002/art.20405

Hunter D, York M, Chaisson C, Woods R, Niu J, Zhang Y (2006) Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 33:1341–1345

Primatesta P, Plana E, Rothenbacher D (2011) Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 12:103. https://doi.org/10.1186/1471-2474-12-103

Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, Neogi T (2012) Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 71:1448–1453. https://doi.org/10.1136/annrheumdis-2011-201215

Gaffo A, Dalbeth N, Saag K et al (2018) Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol 70:462–467. https://doi.org/10.1002/art.40381